Brioli Annamaria, Tacchetti Paola, Zamagni Elena, Cavo Michele
"Seràgnoli" Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
Expert Rev Anticancer Ther. 2014 May;14(5):581-94. doi: 10.1586/14737140.2014.884930. Epub 2014 Mar 3.
The recent availability of novel agents has substantially improved the outcomes of patients with Multiple Myeloma (MM). Achieving the deepest level of complete response and maintaining a sustained remission are important steps towards MM cure. To achieve this goal, consolidation and maintenance therapies are currently incorporated into the modern therapeutic paradigm. The excellent activity shown by new drugs has led to their investigational use as maintenance therapy. However, despite promising results of continuous treatment with the novel agents, consensus regarding maintenance therapy still lacks. This review will focus on maintenance therapy, offering an overview of the different strategies available in MM. The issue of continuous treatment in the light of new biological discoveries, including intra-clonal heterogeneity, will also be addressed.
新型药物的近期问世显著改善了多发性骨髓瘤(MM)患者的治疗结果。实现最深程度的完全缓解并维持持续缓解是迈向治愈MM的重要步骤。为实现这一目标,巩固和维持治疗目前已纳入现代治疗模式。新药所展现出的卓越活性促使其被用于维持治疗的研究。然而,尽管新型药物持续治疗取得了令人鼓舞的结果,但关于维持治疗仍缺乏共识。本综述将聚焦于维持治疗,概述MM中可用的不同策略。还将探讨鉴于新的生物学发现(包括克隆内异质性)而进行持续治疗的问题。